No. |
Variant name |
Chromosome position |
Chromatin state |
Related regulatory elements |
Target genes |
Extended variants |
Associated traits |
1 |
rs555140196 |
chr3:191063096-191063097 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
2 |
rs140396585 |
chr3:191063103-191063104 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
3 |
rs149944459 |
chr3:191063172-191063173 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
4 |
rs111616412 |
chr3:191063173-191063174 |
Enhancers Weak transcription Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
5 |
rs576371562 |
chr3:191063337-191063338 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
6 |
rs188866687 |
chr3:191063348-191063349 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
7 |
rs548927884 |
chr3:191063419-191063420 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
8 |
rs201256127 |
chr3:191063471-191063472 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
9 |
rs568815173 |
chr3:191063493-191063494 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
10 |
rs541899531 |
chr3:191063524-191063525 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
11 |
rs145038742 |
chr3:191063534-191063535 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
12 |
rs145093554 |
chr3:191063553-191063554 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
13 |
rs543927623 |
chr3:191063567-191063568 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
14 |
rs193207746 |
chr3:191063619-191063620 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
15 |
rs142163773 |
chr3:191063639-191063640 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
16 |
rs185210521 |
chr3:191063675-191063676 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
17 |
rs6777160 |
chr3:191063680-191063681 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
18 |
rs72208279 |
chr3:191063693-191063694 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
19 |
rs6801942 |
chr3:191063743-191063744 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
20 |
rs549225072 |
chr3:191063766-191063767 |
Weak transcription Enhancers Flanking Active TSS
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
21 |
rs188922624 |
chr3:191063886-191063887 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
22 |
rs530887073 |
chr3:191063887-191063888 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
23 |
rs146626678 |
chr3:191063902-191063903 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
24 |
rs191797765 |
chr3:191063965-191063966 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
25 |
rs377671483 |
chr3:191063973-191063974 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
26 |
rs539935378 |
chr3:191063984-191063985 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
27 |
rs183916275 |
chr3:191063992-191063993 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
28 |
rs115227932 |
chr3:191064030-191064031 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
29 |
rs535790811 |
chr3:191064067-191064068 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
30 |
rs371250017 |
chr3:191064085-191064086 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
31 |
rs556000932 |
chr3:191064090-191064091 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
32 |
rs188407898 |
chr3:191064103-191064104 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
33 |
rs537409720 |
chr3:191064128-191064129 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
34 |
rs180945852 |
chr3:191064228-191064229 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
35 |
rs185891607 |
chr3:191064267-191064268 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
36 |
rs539922794 |
chr3:191064287-191064288 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
37 |
rs564237632 |
chr3:191064305-191064306 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
38 |
rs560104463 |
chr3:191064334-191064335 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
39 |
rs573751640 |
chr3:191064342-191064343 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
40 |
rs542560816 |
chr3:191064352-191064353 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
41 |
rs190412052 |
chr3:191064357-191064358 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
42 |
rs147898191 |
chr3:191064368-191064369 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
43 |
rs551039771 |
chr3:191064441-191064442 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
44 |
rs4677735 |
chr3:191064528-191064529 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
mRNA abundance
|
45 |
rs533501769 |
chr3:191064567-191064568 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
46 |
rs182347271 |
chr3:191064568-191064569 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
47 |
rs566976016 |
chr3:191064632-191064633 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
48 |
rs16866496 |
chr3:191064647-191064648 |
Weak transcription Enhancers
|
n/a
|
n/a
|
LD-proxies of rSNPOverlapped rCNV
|
n/a
|
49 |
rs375684484 |
chr3:191064686-191064687 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|
50 |
rs141621183 |
chr3:191064773-191064774 |
Weak transcription Enhancers
|
n/a
|
n/a
|
Overlapped CNVs
|
n/a
|